- Home
- OB vs FULC Comparison
OB vs FULC Comparison
Compare OB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OB
- FULC
- Stock Information
- Founded
- OB 2006
- FULC 2015
- Country
- OB United States
- FULC United States
- Employees
- OB N/A
- FULC N/A
- Industry
- OB Industrial Machinery/Components
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- OB Industrials
- FULC Health Care
- Exchange
- OB Nasdaq
- FULC Nasdaq
- Market Cap
- OB 219.5M
- FULC 221.5M
- IPO Year
- OB 2021
- FULC 2019
- Fundamental
- Price
- OB $5.10
- FULC $2.97
- Analyst Decision
- OB Buy
- FULC Hold
- Analyst Count
- OB 5
- FULC 10
- Target Price
- OB $5.50
- FULC $7.44
- AVG Volume (30 Days)
- OB 116.7K
- FULC 816.2K
- Earning Date
- OB 11-07-2024
- FULC 11-13-2024
- Dividend Yield
- OB N/A
- FULC N/A
- EPS Growth
- OB N/A
- FULC N/A
- EPS
- OB N/A
- FULC N/A
- Revenue
- OB $903,518,000.00
- FULC $80,871,000.00
- Revenue This Year
- OB $1.24
- FULC $2,821.96
- Revenue Next Year
- OB $7.66
- FULC N/A
- P/E Ratio
- OB N/A
- FULC N/A
- Revenue Growth
- OB N/A
- FULC 2987.86
- 52 Week Low
- OB $3.42
- FULC $2.86
- 52 Week High
- OB $5.48
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- OB 60.54
- FULC 32.31
- Support Level
- OB $4.91
- FULC $2.86
- Resistance Level
- OB $5.48
- FULC $3.94
- Average True Range (ATR)
- OB 0.20
- FULC 0.22
- MACD
- OB 0.03
- FULC -0.00
- Stochastic Oscillator
- OB 69.60
- FULC 10.19
About OB Outbrain Inc.
Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.